Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

Hao Zuo; Dengbao Yang; Qiwen Yang; Haidong Tang; Yang-Xin Fu; Yihong Wan

doi:10.1038/s41467-020-15429-z

Nature Communications (Mar 2020)

Differential regulation of breast cancer bone metastasis by PARP1 and PARP2

Hao Zuo,
Dengbao Yang,
Qiwen Yang,
Haidong Tang,
Yang-Xin Fu,
Yihong Wan

Affiliations

Hao Zuo: Department of Pharmacology, The University of Texas Southwestern Medical Center
Dengbao Yang: Department of Pharmacology, The University of Texas Southwestern Medical Center
Qiwen Yang: Department of Pharmacology, The University of Texas Southwestern Medical Center
Haidong Tang: Department of Pathology, The University of Texas Southwestern Medical Center
Yang-Xin Fu: Department of Pathology, The University of Texas Southwestern Medical Center
Yihong Wan: Department of Pharmacology, The University of Texas Southwestern Medical Center

DOI: https://doi.org/10.1038/s41467-020-15429-z
Journal volume & issue: Vol. 11, no. 1
pp. 1 – 10

Abstract

Read online

The effect of PARP inhibitors on bone mass and bone metastasis are unclear. Here, the authors show that PARP1/2 dual inhibitors may increase cancer bone metastasis through PARP2-dependent regulation of immature myeloid cells, and cause bone loss through PARP1/2-dependent regulation of osteoclasts.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal